A Phase 1 study by Dr. Noffar Bar
@yale-hematology.bsky.social shows subcutaneous alnuctamab #ALNUC is active in #RRMM, with a 58–71% response rate, ~50% of patients achieving MRD negativity, and better safety than IV dosing. #multiplemyeloma
www.nature.com/articles/s41...
0
0
0
0